Other

Bruker Daltonik Gmbh

Bruker Daltonics Gmbh & Co. Kg

Sören-Oliver Deininger

Martin Schürenberg

Alice Ly

Detlev Suckau

Eckhard Belau

Eryk Wolski

Christian Albers

Sandra Rauser

Axel Walch

Detlef Suckau

The invention proposes preparing biological samples for spectrometry which contain cell structures and/or whole cells of human or animal origin (e.g. thin human and animal tissue sections) or prokaryotes (e.g. microorganisms), and which require constant relative humidity, in a temperature-controlled gas volume whose humidity is determined by a saturated substance solution, for example a suitable salt solution. The invention exploits a physico-chemical phenomenon called 'deliquescence', which manifests itself by keeping the relative humidity above the saturated substance solution constant with a high degree of precision when a specified temperature is maintained. Pure succinic acid exhibits deliquescence at approx. 99% relative humidity, for example. Since an enormous variety of deliquescent salts and other suitable substances are available, it is possible to find the suitable substance for almost any desired relative humidity, with adjustment of the temperature, where necessary.

Humidity stabilization during the preparation of biological samples for spectrometry

The invention relates to the identification and visualization of the spatial distribution of particular tissue states in histological tissue sections from mass spectrometric signals acquired with spatial resolution. The invention proposes a method by means of which regions of the tissue with similar mass spectra are found automatically, and it is further proposed that mass spectra of these regions are summed in order to improve the spectral quality to such an extent that known markers for tissue degenerations can be identified with increased certainty. Regions of similar mass spectra can be interconnected on a large scale, but can also be isolated from each other on a small scale.

Mass spectrometric determination of particular tissue states

The invention relates to a method for monitoring a quality of preparation workflows of analytical tissue sections for mass spectrometric imaging using a control sample to be processed and measured alongside the analytical tissue sections on the same sample support and ascertaining if characteristics of the control sample measurement fit into a range of characteristics of separate reference measurements from the same type of control sample.

Method for monitoring the quality of mass spectrometric imaging preparation workflows

Mass spectra acquired by imaging mass spectrometry (IMS), in particular MALDI imaging of tissue sections, are each normalized by one of: the p-norm of the mass spectrum transformed by applying an exclusion list, the p-norm of the mass spectrum transformed by square rooting the intensity values, the median of the mass spectrum, and the median absolute deviation of the noise level of the mass spectrum.

Normalization of mass spectra acquired by mass spectrometric imaging

The invention relates to a method for evaluating a quality of preparations of analytical tissue sections for mass spectrometric imaging using a reference sample to be processed and measured alongside the analytical tissue sections, and a kit-of-parts for a mass spectrometric imaging experiment including such reference sample.

Method for evaluating the quality of mass spectrometric imaging preparations and kit-of-parts therefor

A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.

Determining an expression status of human epidermal growth factor receptor 2 (HER2) in a biological sample

An analysis of type, state or other distinguishing features of individual cells from body fluids, smears or tissues includes the steps of depositing the cells, with a minimum possible overlap, on a mass spectrometric sample support, determining the coordinates of the cells, coating the sample support with a layer of small crystals of a matrix substance, positioning the cells, inside a mass spectrometer, according to their known coordinates with a movement device into the position of the laser focus, acquiring mass spectra of the individual cells with ionization of the cell components by matrix assisted laser desorption, and using the mass spectra for an analysis of type, state or other distinguishing features of the cells.

Growing community of inventors

Leipzig, Germany

Sören-Oliver Deininger